Back to today’s briefing

Story perspectives

AstraZeneca Halts Prostate Cancer Trial Amid Revenue Surge

5/1/2025

44 8

Summary

Story summary

AstraZeneca has made the tough decision to stop its prostate cancer trial for the AKT inhibitor Truqap after it fell short of survival goals. This trial, which included over 1,000 patients battling advanced prostate cancer, marks a significant setback. However, the company still celebrated a 10% revenue boost to $13.6 billion in Q1 2025, fueled by strong performance in Oncology and BioPharmaceuticals.

1 of 1

Story summary

AstraZeneca has made the tough decision to stop its prostate cancer trial for the AKT inhibitor Truqap after it fell short of survival goals. This trial, which included over 1,000 patients battling advanced prostate cancer, marks a significant setback. However, the company still celebrated a 10% revenue boost to $13.6 billion in Q1 2025, fueled by strong performance in Oncology and BioPharmaceuticals.